Cancer can raise blood pressure, but usually not through the disease itself growing in your body. The most common route is through cancer treatment: drugs that target tumor blood supply, hormone therapies, and even radiation can push blood pressure significantly higher. A smaller number of rare tumors directly produce hormones that spike blood pressure, sometimes as the very first sign that cancer is present. The relationship between cancer and hypertension turns out to run in both directions, with shared biology linking the two conditions in ways researchers are still untangling.
Tumors That Directly Raise Blood Pressure
A handful of tumor types can drive blood pressure up on their own, without any treatment involved. These are uncommon, but they illustrate how directly a tumor can hijack the body’s blood pressure controls.
The best-known example is a pheochromocytoma, a tumor that grows in the adrenal glands and pumps out adrenaline and related hormones called catecholamines. That flood of stress hormones causes chronic or sudden surges of high blood pressure, along with sweating, headaches, and a pounding heart.1PubMed. Pheochromocytomas and Hypertension Closely related tumors called paragangliomas, which grow outside the adrenal glands but secrete the same hormones, carry similar cardiovascular risks.2Journal of Human Hypertension. Ambulatory blood pressure monitoring before and after resection of catecholamine-secreting pheochromocytoma or paraganglioma These tumors are rare, but when they are found and surgically removed, blood pressure often returns to normal.
Another category involves tumors that secrete renin, the enzyme that kicks off the body’s main blood-pressure-raising hormonal chain. A reninoma is a small, benign kidney tumor that overproduces renin, leading to severe hypertension that responds well to drugs targeting that hormonal pathway. Patients often have years of unexplained headaches before anyone figures out the cause.3PubMed Central. Reninoma: an uncommon cause of Renin-mediated hypertension In rare instances, even certain kidney cancers can secrete renin. One reported case involved a young woman with six months of uncontrolled high blood pressure; after her kidney tumor was removed, her blood pressure returned to normal within a month.4Urology Case Reports. Renin-secreting chromophobe renal cell carcinoma: An uncommon cause of secondary hypertension in a young female Older case series confirm the same pattern: remove the renin-secreting tumor, and both hypertension and the low potassium levels it causes resolve.5PubMed. Diagnosis and treatment of renin-secreting tumors. Report of three cases.
A third mechanism involves tumors that produce hormones mimicking the pituitary gland’s signals. Some cancers, particularly small cell lung carcinoma, secrete ACTH, the hormone that tells the adrenal glands to produce cortisol. The result is a condition called ectopic Cushing’s syndrome: the body is flooded with cortisol, which in excess activates receptors that cause the kidneys to retain salt and water. This leads to hypertension alongside muscle weakness, high blood sugar, and dangerously low potassium.6PubMed Central. Ectopic Cushing’s Syndrome as the First Presenting Sign of Small Cell Lung Carcinoma
Brain tumors can also raise blood pressure through a different route entirely. When a tumor increases pressure inside the skull, the body responds by raising systemic blood pressure to keep blood flowing to the brain. This reflex, driven by changes in carbon dioxide levels around the brainstem, is the body’s emergency measure to maintain brain perfusion. It produces a distinctive pattern of rising blood pressure along with changes in heart rate and breathing.
Cancer Drugs That Push Blood Pressure Up
For most people with cancer, the more relevant concern is treatment-induced hypertension. Several classes of cancer drugs are well established to raise blood pressure, and in some cases the effect is both common and significant.
The biggest culprits are drugs that block a protein called VEGF, which tumors rely on to grow new blood vessels and feed themselves. By cutting off that blood vessel growth, these drugs starve the tumor, but they also interfere with the normal maintenance of healthy blood vessels throughout the body. Research in patients with metastatic kidney cancer found that VEGF-blocking drugs suppress production of nitric oxide, the molecule that keeps blood vessels relaxed and dilated.7PubMed Central. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors Less nitric oxide means stiffer, narrower vessels and higher blood pressure.
This is not a rare side effect. Hypertension is one of the most common problems with this entire class of drugs.8PubMed Central. Tyrosine kinase inhibitor-induced hypertension—marker of anti-tumour treatment efficacy or cardiovascular risk factor? Across different drugs and trials, rates of hypertension range widely depending on the specific agent. Among small-molecule drugs targeting VEGF pathways, roughly 30 to 80 percent of patients develop some degree of blood pressure elevation. Individual drugs show a wide spread: about 40 percent with pazopanib, up to roughly two-thirds with ponatinib, and varying rates with others like sorafenib, sunitinib, and axitinib.9Signal Transduction and Targeted Therapy. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management Antibody-based VEGF blockers like bevacizumab carry similar hypertension risks.
Ibrutinib, a drug used for blood cancers like chronic lymphocytic leukemia, tells a different but equally striking story. In one study, about a third of patients developed new hypertension during treatment, with a similar proportion reaching readings high enough to be classified as severe.10JAMA Network Open. Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia Longer-term follow-up of patients on ibrutinib in clinical trials found that new-onset or worsening hypertension affected roughly two-thirds of patients overall.11PubMed Central. Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib on clinical trials: focus on hypertension and cardiovascular toxicity The mechanism is different from VEGF inhibitors and appears to involve the drug’s effects on pathways beyond its primary cancer target, but the clinical result is the same: blood pressure that needs active monitoring and management.
When Rising Blood Pressure Signals the Drug Is Working
Here is where the story gets counterintuitive. For some VEGF-targeting drugs, developing hypertension during treatment appears to be a sign that the drug is effectively doing its job against the tumor. This has been studied most closely with axitinib, a drug used for kidney cancer. Patients whose diastolic blood pressure rose above 90 during treatment had a substantially lower risk of death compared to those whose blood pressure stayed below that threshold. They also had better tumor response rates and longer progression-free survival.12Clinical Cancer Research. Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
This creates a genuine clinical tension. Oncologists want to see evidence that the drug is hitting its target, and rising blood pressure may be that evidence. But unchecked hypertension damages the heart, kidneys, and brain over time. The current approach is to manage the hypertension aggressively with blood pressure medications while continuing cancer treatment, rather than reducing the cancer drug dose. Screening and early treatment of hypertension in cancer patients are considered essential to avoid organ damage and to keep patients on effective therapy without interruption.13PubMed Central. Management of hypertension in patients with cancer: challenges and considerations
Radiation, Steroids, and Other Indirect Routes
Cancer treatment’s blood pressure effects extend well beyond targeted drugs. Radiation therapy aimed at the head and neck can damage the carotid sinus, the pressure sensor in the neck that tells the brain what blood pressure is. When this sensor stops working properly, the brain loses its ability to make fine adjustments to blood pressure. The result can be wild swings between dangerously high readings and sudden drops, a condition called baroreflex failure. One case report described a patient with both severe labile hypertension and fainting episodes years after radiation for head and neck cancer, eventually traced to this disrupted signaling.14Circulation. Abstract 4369880: Beyond the Cuff: Diagnosing Baroreceptor Failure After Head and Neck Radiation This is an under-recognized cause of hypertension, partly because the connection between neck radiation and blood pressure problems may not be obvious years after treatment ends.
Supportive medications given alongside cancer therapy add another layer. Corticosteroids, commonly prescribed to manage nausea, inflammation, or immune reactions during chemotherapy, raise blood pressure through fluid retention and other hormonal effects. Calcineurin inhibitors used after bone marrow transplants, nonsteroidal anti-inflammatory drugs for pain, and anti-androgen hormone therapies for prostate cancer all have blood-pressure-raising potential as well.15PubMed Central. Cancer Therapy-Related Hypertension: A Scientific Statement From the American Heart Association For a patient receiving multiple treatments simultaneously, these effects can stack.
Pain itself is another contributor. Research has consistently found a positive correlation between pain and systolic blood pressure in cancer patients. The body’s acute stress response to uncontrolled pain activates the same fight-or-flight hormonal pathways that raise heart rate and constrict blood vessels. This means that a blood pressure reading taken during a pain flare may not reflect a patient’s baseline cardiovascular status at all.
Shared Risk Factors Running in Both Directions
The relationship between cancer and hypertension is not just one-directional. The two conditions share underlying biology, including chronic inflammation, oxidative stress, and metabolic disruption.16PubMed Central. Comorbidity of hypertension and lung cancer: interplay of genetics and environment Both conditions are more common in people who smoke, are overweight, eat high-sodium diets, and are physically inactive. This overlap means many patients already have hypertension when they are diagnosed with cancer, and the cancer treatment then pushes their blood pressure even higher.
The reverse question, whether hypertension raises cancer risk, has been studied most extensively for kidney cancer. A large population-based study found that people with hypertension had roughly twice the incidence rate of kidney cancer compared to those without, with an adjusted hazard ratio of about 1.12 even after accounting for other factors.17PubMed Central. Association of Hypertension and Blood Pressure With Kidney Cancer Risk: A Nationwide Population-Based Cohort Study An earlier study of men found that higher diastolic and systolic blood pressures were consistently associated with greater kidney cancer risk, and this association held even after excluding the first five years of follow-up to account for the possibility that undetected early cancer was causing the blood pressure rise.18PubMed. Obesity, hypertension, and the risk of kidney cancer in men The mechanism is not entirely clear, but chronic hypertension may damage the kidney in ways that promote tumor development over time.
Childhood Cancer Survivors and Lasting Effects
The blood pressure consequences of cancer treatment can show up decades after the cancer itself is gone, and this is especially relevant for people treated during childhood. In a study of long-term childhood cancer survivors assessed at a median age of about 19, roughly 15 percent had elevated blood pressure, and about 28 percent had at least one kidney-related or blood-pressure-related problem. The combination of radiation therapy and surgical removal of a kidney carried a particularly high risk, with nearly five times the odds of elevated blood pressure compared to survivors who had neither.19PubMed Central. Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors
The mechanisms behind this long-term risk involve damage to blood vessel linings, changes in how the nervous system regulates blood pressure, and disruption of the kidneys’ hormonal role in blood pressure control, all resulting from prior cancer treatments like chemotherapy and radiation.20PubMed Central. Hypertension in Childhood Cancer Survivors: Causes, Screening, and Management Male sex, higher body weight, and longer time since treatment all made elevated blood pressure more likely.19PubMed Central. Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors This means that someone treated for leukemia at age five may face blood pressure screening recommendations well into adulthood that differ from the general population’s.
Keeping Blood Pressure Manageable During Treatment
One of the more practical findings in recent years involves something as simple as dietary salt. A study in patients starting VEGF-blocking drugs found that restricting sodium intake during treatment blunted the blood pressure rise by about 7 points of mean arterial pressure compared to a cycle without salt restriction. The low-sodium approach also prevented a shift in hormonal markers associated with VEGF-inhibitor hypertension and reduced the onset of protein in the urine, a sign of kidney stress.21British Journal of Cancer. Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension Salt restriction is not a substitute for blood pressure medication when readings climb high, but it represents a low-risk complementary strategy that patients can act on immediately.
Monitoring itself presents challenges. Blood pressure in cancer patients can fluctuate significantly day to day, influenced by pain levels, medication timing, anxiety around clinic visits, and the effects of treatment cycles. Home blood pressure monitoring has been recommended as a way to get a more accurate picture of what is really happening between clinic visits and to help adjust medications more precisely. For patients on drugs known to cause hypertension, regular home readings give clinicians a longitudinal view that a single office measurement simply cannot provide.13PubMed Central. Management of hypertension in patients with cancer: challenges and considerations
The American Heart Association has formally recognized cancer-treatment-related hypertension as a distinct clinical entity deserving targeted guidelines.15PubMed Central. Cancer Therapy-Related Hypertension: A Scientific Statement From the American Heart Association The emphasis across current guidance is clear: do not wait for hypertension to become severe before treating it, because doing so risks both organ damage and disruption of the cancer treatment that may be keeping the patient alive. The goal is to treat blood pressure aggressively enough that the cancer drug can continue at full dose, a balancing act that requires coordination between oncology and cardiology teams that historically have not talked to each other as much as they should.